<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Bone Biologics Corp — News on 6ix</title>
<link>https://6ix.com/company/bone-biologics-corp</link>
<description>Latest news and press releases for Bone Biologics Corp on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 08 Jan 2026 13:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/bone-biologics-corp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354b3a78dffbe2df0e5018.webp</url>
<title>Bone Biologics Corp</title>
<link>https://6ix.com/company/bone-biologics-corp</link>
</image>
<item>
<title>Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook</title>
<link>https://6ix.com/company/bone-biologics-corp/news/bone-biologics-highlights-2025-key-130000599</link>
<guid isPermaLink="true">https://6ix.com/company/bone-biologics-corp/news/bone-biologics-highlights-2025-key-130000599</guid>
<pubDate>Thu, 08 Jan 2026 13:00:00 GMT</pubDate>
<description>Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened balance sheet, and maintained Nasdaq complianceBURLINGTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today summarized key corporate, scientific, and operational milestones achieved during 2025 and outlined its strategic outlook for 2026. “We executed wit</description>
</item>
<item>
<title>Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months</title>
<link>https://6ix.com/company/bone-biologics-corp/news/bone-biologics-improves-extension-rhnell-130000900</link>
<guid isPermaLink="true">https://6ix.com/company/bone-biologics-corp/news/bone-biologics-improves-extension-rhnell-130000900</guid>
<pubDate>Tue, 23 Dec 2025 13:00:00 GMT</pubDate>
<description>Milestone advances manufacturing readiness and supports long-term commercialization strategyBURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces it has received confirmation that the shelf life of its rhNELL-1 product has been extended to 24 months, delivering on previously communicated forecasts. The extended shelf life is validated by o</description>
</item>
<item>
<title>Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook</title>
<link>https://6ix.com/company/bone-biologics-corp/news/bone-biologics-ceo-issues-letter-110000958</link>
<guid isPermaLink="true">https://6ix.com/company/bone-biologics-corp/news/bone-biologics-ceo-issues-letter-110000958</guid>
<pubDate>Thu, 04 Sep 2025 11:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., September 04, 2025--Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that President and Chief Executive Officer Jeffrey Frelick has issued the following letter to stockholders.</description>
</item>
<item>
<title>Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference</title>
<link>https://6ix.com/company/bone-biologics-corp/news/bone-biologics-participate-h-c-110000424</link>
<guid isPermaLink="true">https://6ix.com/company/bone-biologics-corp/news/bone-biologics-participate-h-c-110000424</guid>
<pubDate>Wed, 03 Sep 2025 11:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., September 03, 2025--Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, President and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025.</description>
</item>
<item>
<title>Bone Biologics Announces Closing of $5.0 Million Public Offering</title>
<link>https://6ix.com/company/bone-biologics-corp/news/bone-biologics-announces-closing-5-201000153</link>
<guid isPermaLink="true">https://6ix.com/company/bone-biologics-corp/news/bone-biologics-announces-closing-5-201000153</guid>
<pubDate>Mon, 30 Jun 2025 20:10:00 GMT</pubDate>
<description>BURLINGTON, Mass., June 30, 2025--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), Series D warrants to purchase up to 1,250,000 shares of common stock and Series E short-term warrants to purchase up to 1,250,000 shares of c</description>
</item>
<item>
<title>Bone Biologics Announces Pricing of $5.0 Million Public Offering</title>
<link>https://6ix.com/company/bone-biologics-corp/news/bone-biologics-announces-pricing-5-131000042</link>
<guid isPermaLink="true">https://6ix.com/company/bone-biologics-corp/news/bone-biologics-announces-pricing-5-131000042</guid>
<pubDate>Fri, 27 Jun 2025 13:10:00 GMT</pubDate>
<description>BURLINGTON, Mass., June 27, 2025--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), Series D warrants to purchase up to 1,250,000 shares of common stock and Series E short-term warrants to purchase up to 1,250,000 shares of common stock, at a pub</description>
</item>
<item>
<title>Bone Biologics Files Patent Application for Bone Regeneration Technology</title>
<link>https://6ix.com/company/bone-biologics-corp/news/bone-biologics-files-patent-application-110000367</link>
<guid isPermaLink="true">https://6ix.com/company/bone-biologics-corp/news/bone-biologics-files-patent-application-110000367</guid>
<pubDate>Fri, 27 Jun 2025 11:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., June 27, 2025--Bone Biologics files U.S. patent application for bone regeneration technology</description>
</item>
<item>
<title>Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements</title>
<link>https://6ix.com/company/bone-biologics-corp/news/bone-biologics-regains-compliance-nasdaq-202000803</link>
<guid isPermaLink="true">https://6ix.com/company/bone-biologics-corp/news/bone-biologics-regains-compliance-nasdaq-202000803</guid>
<pubDate>Thu, 26 Jun 2025 20:20:00 GMT</pubDate>
<description>BURLINGTON, Mass., June 26, 2025--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing on the Nasdaq Capital Market. Bone Biologics is now in complian</description>
</item>
<item>
<title>Bone Biologics Announces 1-for-6 Reverse Stock Split</title>
<link>https://6ix.com/company/bone-biologics-corp/news/bone-biologics-announces-1-6-120000761</link>
<guid isPermaLink="true">https://6ix.com/company/bone-biologics-corp/news/bone-biologics-announces-1-6-120000761</guid>
<pubDate>Fri, 06 Jun 2025 12:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., June 06, 2025--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-6. The reverse stock split will take effect as of 12:01 a.m. ET, on Tuesday, June 10, 2025, and shares of Bone Biologics are expected to trade on a post-split basis on Nasdaq under the existing trading symbol, "BBLG," at</description>
</item>
<item>
<title>Bone Biologics Appoints Phillip T. Meikle to its Board of Directors</title>
<link>https://6ix.com/company/bone-biologics-corp/news/bone-biologics-appoints-phillip-t-meikle-to-its-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/bone-biologics-corp/news/bone-biologics-appoints-phillip-t-meikle-to-its-board-of-directors</guid>
<pubDate>Mon, 21 Oct 2024 04:00:00 GMT</pubDate>
<description>Brings 30+ years of commercial experience in the orthopedic and spine industry BURLINGTON, Mass.--(BUSINESS WIRE)-- Bone Biologics Corporation (“Bone</description>
</item>
<item>
<title>Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds</title>
<link>https://6ix.com/company/bone-biologics-corp/news/bone-biologics-announces-exercise-of-warrants-for-dollar21-million-gross-proceeds</link>
<guid isPermaLink="true">https://6ix.com/company/bone-biologics-corp/news/bone-biologics-announces-exercise-of-warrants-for-dollar21-million-gross-proceeds</guid>
<pubDate>Fri, 02 Aug 2024 04:00:00 GMT</pubDate>
<description>BURLINGTON, Mass.--(BUSINESS WIRE)-- Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic</description>
</item>
<item>
<title>Bone Biologics Announces Pricing of $2.0 Million Public Offering</title>
<link>https://6ix.com/company/bone-biologics-corp/news/bone-biologics-announces-pricing-of-dollar20-million-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/bone-biologics-corp/news/bone-biologics-announces-pricing-of-dollar20-million-public-offering</guid>
<pubDate>Mon, 04 Mar 2024 05:00:00 GMT</pubDate>
<description>BURLINGTON, Mass.--(BUSINESS WIRE)-- Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic</description>
</item>
<item>
<title>Bone Biologics Reports Progress With NB1 Clinical Program</title>
<link>https://6ix.com/company/bone-biologics-corp/news/bone-biologics-reports-progress-with-nb1-clinical-program</link>
<guid isPermaLink="true">https://6ix.com/company/bone-biologics-corp/news/bone-biologics-reports-progress-with-nb1-clinical-program</guid>
<pubDate>Fri, 01 Mar 2024 05:00:00 GMT</pubDate>
<description>BURLINGTON, Mass.--(BUSINESS WIRE)-- Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, reports</description>
</item>
<item>
<title>Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors</title>
<link>https://6ix.com/company/bone-biologics-corp/news/bone-biologics-appoints-healthcare-finance-veteran-robert-e-gagnon-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/bone-biologics-corp/news/bone-biologics-appoints-healthcare-finance-veteran-robert-e-gagnon-to-board-of-directors</guid>
<pubDate>Thu, 11 Jan 2024 05:00:00 GMT</pubDate>
<description>Brings 20+ years of experience in finance and business operations at both public and private life sciences companies BURLINGTON, Mass.--(BUSINESS WIRE)--</description>
</item>
<item>
<title>Bone Biologics Announces 1-for-8 Reverse Stock Split</title>
<link>https://6ix.com/company/bone-biologics-corp/news/bone-biologics-announces-1-for-8-reverse-stock-split</link>
<guid isPermaLink="true">https://6ix.com/company/bone-biologics-corp/news/bone-biologics-announces-1-for-8-reverse-stock-split</guid>
<pubDate>Mon, 18 Dec 2023 05:00:00 GMT</pubDate>
<description>BURLINGTON, Mass.--(BUSINESS WIRE)-- Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic</description>
</item>
<item>
<title>Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/bone-biologics-corp/news/bone-biologics-announces-registered-direct-offering-priced-at-the-market-under-nasdaq-rules</link>
<guid isPermaLink="true">https://6ix.com/company/bone-biologics-corp/news/bone-biologics-announces-registered-direct-offering-priced-at-the-market-under-nasdaq-rules</guid>
<pubDate>Thu, 16 Nov 2023 05:00:00 GMT</pubDate>
<description>BURLINGTON, Mass.--(BUSINESS WIRE)-- Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today</description>
</item>
<item>
<title>Bone Biologics Provides Scientific Update on NB1 Bone Graft Device</title>
<link>https://6ix.com/company/bone-biologics-corp/news/bone-biologics-provides-scientific-update-on-nb1-bone-graft-device</link>
<guid isPermaLink="true">https://6ix.com/company/bone-biologics-corp/news/bone-biologics-provides-scientific-update-on-nb1-bone-graft-device</guid>
<pubDate>Tue, 26 Sep 2023 04:00:00 GMT</pubDate>
<description>BURLINGTON, Mass.--(BUSINESS WIRE)-- Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, provides an</description>
</item>
<item>
<title>Bone Biologics Prices $5.0 Million Underwritten Public Offering</title>
<link>https://6ix.com/company/bone-biologics-corp/news/bone-biologics-prices-dollar50-million-underwritten-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/bone-biologics-corp/news/bone-biologics-prices-dollar50-million-underwritten-public-offering</guid>
<pubDate>Wed, 14 Jun 2023 04:00:00 GMT</pubDate>
<description>BURLINGTON, Mass.--(BUSINESS WIRE)-- Bone Biologics Corporation (NASDAQ: BBLG) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for</description>
</item>
<item>
<title>Bone Biologics Effects 1-for-30 Reverse Stock Split</title>
<link>https://6ix.com/company/bone-biologics-corp/news/bone-biologics-effects-1-for-30-reverse-stock-split</link>
<guid isPermaLink="true">https://6ix.com/company/bone-biologics-corp/news/bone-biologics-effects-1-for-30-reverse-stock-split</guid>
<pubDate>Tue, 06 Jun 2023 04:00:00 GMT</pubDate>
<description>BURLINGTON, Mass.--(BUSINESS WIRE)-- Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces</description>
</item>
<item>
<title>Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia</title>
<link>https://6ix.com/company/bone-biologics-corp/news/bone-biologics-receives-human-research-ethics-committee-approval-to-begin-pilot-clinical-trial-with-nb1-in-spinal-fusion-patients-in-australia</link>
<guid isPermaLink="true">https://6ix.com/company/bone-biologics-corp/news/bone-biologics-receives-human-research-ethics-committee-approval-to-begin-pilot-clinical-trial-with-nb1-in-spinal-fusion-patients-in-australia</guid>
<pubDate>Tue, 11 Apr 2023 04:00:00 GMT</pubDate>
<description>Company plans to begin 30-patient trial later this year BURLINGTON, Mass.--(BUSINESS WIRE)-- Bone Biologics Corporation (NASDAQ: BBLG), a developer of</description>
</item>
</channel>
</rss>